Your kidneys hold enormous power over your blood pressure. Each day they filter roughly 180 litres of plasma, and a critical circuit in the distal nephron decides how much sodium — and with it, water — gets reclaimed before the urine exits the body. The master regulator of that circuit is NEDD4L: an E3 ubiquitin ligase¹¹ E3 ubiquitin ligase
An enzyme that attaches ubiquitin tags to target proteins, marking them for removal from the cell surface that controls how many epithelial sodium channels (ENaC) remain active on the luminal membrane of kidney tubule cells at any given moment. When NEDD4L functions efficiently, it ubiquitinates ENaC subunits and pulls them off the membrane, limiting sodium reabsorption and keeping blood pressure in check. When NEDD4L function is reduced or its interaction with ENaC is weakened, the channels linger longer on the cell surface, sodium reabsorption climbs, and blood pressure follows.

rs8094327 is an intronic variant within NEDD4L on chromosome 18q21 that sits in strong linkage disequilibrium²² linkage disequilibrium
LD means two variants are co-inherited so frequently that tracking one effectively tracks both with rs4149601 (r² ≈ 0.95), the primary functional variant at this locus. rs4149601 is a G→A substitution at the last nucleotide of exon 1 that creates a cryptic splice site. The G allele preserves the standard transcript encoding a full-length protein with an intact C2 calcium-sensing domain; the A allele generates an alternatively spliced isoform that lacks the C2 domain, enabling stronger NEDD4L–ENaC binding and more efficient channel degradation. This locus illustrates a case where the "risk" and "protective" labels run counter to intuition: the G allele — which preserves normal NEDD4L structure — is paradoxically associated with higher salt sensitivity and greater reliance on ENaC-mediated sodium reabsorption, while the A allele generates an isoform that more aggressively downregulates ENaC activity.

The Mechanism

NEDD4L binds to ENaC (alpha, beta, and gamma subunits) through interactions between its WW domains³³ WW domains
Protein-protein interaction modules named for their conserved tryptophan residues and the PY motifs on the cytoplasmic tails of ENaC subunits. Once bound, NEDD4L polyubiquitinates the ENaC subunits, triggering their endocytosis and proteasomal or lysosomal degradation. The net effect is a reduction in the number of active ENaC channels in the apical membrane, which limits transepithelial sodium transport in the collecting duct.

The rs4149601 A allele creates an alternate splice acceptor site that causes preferential deletion of the C2 domain⁴⁴ preferential deletion of the C2 domain
The C2 domain is a calcium-dependent membrane-targeting module that tethers NEDD4L to the plasma membrane. Without the C2 domain, isoform I is constitutively cytoplasmic — but paradoxically this removes a spatial constraint on its WW-domain interactions, resulting in stronger and more efficient ENaC ubiquitination. Carriers of the A allele at rs4149601 (and the correlated A allele at rs8094327) therefore have greater ENaC downregulation capacity, lower basal ENaC surface expression, and lower sodium reabsorption. The G-allele carriers retain the full-length isoform with intact C2 domain but have the less efficient ENaC-downregulating isoform, leaving more ENaC channels active on the surface — raising the sodium reabsorption set point.

The Evidence

This locus has been robustly replicated across multiple independent cohorts. Dahlberg et al. (2007, PLoS ONE)⁵⁵ Dahlberg et al. (2007, PLoS ONE)
Dahlberg et al., Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of Nt-proANP. PLoS One, 2007 demonstrated in 39 normotensive Swedish adults that the GG genotype at rs4149601, when combined with the rs2288774 CC genotype, was associated with dramatically elevated salt sensitivity (median blood pressure increase of 18 mmHg on high salt vs 6 mmHg in non-carriers, p=0.007), significantly lower plasma renin (p=0.005), and higher circulating Nt-proANP — a marker of volume expansion and cardiac stretch. The physiological signature is classic low-renin, volume-dependent hypertension.

Svensson-Färbom et al. (2009)⁶⁶ Svensson-Färbom et al. (2009)
Svensson-Färbom et al., A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension, 2009 confirmed in a larger Swedish cohort that rs4149601 GG individuals had significantly higher diastolic blood pressure, lower plasma renin, and were at increased risk of hypertension. Uniquely, they were less susceptible to orthostatic hypotension — consistent with a higher plasma volume set point that buffers against the blood pressure drop on standing.

Treatment response data from two clinical trials clinched the pharmacogenomic relevance. Svensson-Färbom et al. (2011)⁷⁷ Svensson-Färbom et al. (2011)
Svensson-Färbom et al., A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. Journal of Hypertension, 2011 showed that G-allele carriers on β-blocker or diuretic monotherapy had markedly greater blood pressure reductions (SBP −19.5 vs −15.0 mmHg, p<0.001; DBP −15.4 vs −14.1 mmHg, p=0.02) and a relative risk of cardiovascular disease of 0.52 vs AA homozygotes (95% CI 0.36–0.74, p<0.001) over 4.5 years. Importantly, calcium channel blocker (diltiazem) efficacy was not genotype-dependent.

McDonough et al. (2013)⁸⁸ McDonough et al. (2013)
McDonough et al., Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of Hypertension, 2013 replicated in the PEAR trial (white hypertensive patients on hydrochlorothiazide): rs4149601 G-allele carriers showed significantly greater SBP and DBP reduction (SBP p=0.0303, DBP p=0.0372). The haplotype GC at rs4149601/rs292449 was the strongest predictor (p=0.0006 for SBP). Conversely, AG heterozygotes NOT treated with hydrochlorothiazide showed markedly elevated adverse cardiovascular event risk (OR 10.65, 95% CI 1.18–96.25, p=0.022), underlining that genotype–drug matching matters substantially for this locus.

Long-term cardiovascular data from Dahlberg et al. (2014)⁹⁹ Dahlberg et al. (2014)
Dahlberg et al., Genetic variation in NEDD4L, an epithelial sodium channel regulator, is associated with cardiovascular disease and cardiovascular death. Journal of Hypertension, 2014 followed 27,564 participants from the Malmö Diet and Cancer Study for 14 years. The salt-sensitivity genotype (rs4149601 GG + rs2288774 CC, present in 9.6% of participants) was associated with higher systolic and diastolic blood pressure, cardiovascular disease hazard ratio of 1.13 (95% CI 1.02–1.25), coronary event HR 1.20 (95% CI 1.06–1.37), and borderline cardiovascular mortality HR 1.17 (95% CI 0.99–1.37).

Practical Actions

For G-allele carriers at rs8094327, the underlying biology points toward low-renin, volume-dependent blood pressure elevation. The two most directly relevant practical implications are dietary sodium management and antihypertensive drug selection.

Sodium restriction is disproportionately effective in individuals with ENaC-driven volume expansion. Carriers of the high-salt-sensitivity genotype show nearly three times the blood pressure response to dietary sodium changes compared to non-carriers. Targeting sodium intake below 2,000 mg per day (rather than the standard <2,300 mg guidance) is particularly worth pursuing for GG individuals, who sit at the extreme of the salt-sensitivity spectrum.

Regarding antihypertensives, the evidence is directionally clear: if blood pressure treatment becomes necessary, G-allele carriers respond substantially better to thiazide diuretics and β-blockers than to calcium channel blockers. Coordinating with a physician who is aware of this pharmacogenomic data can improve treatment efficiency and potentially reduce cardiovascular event risk.

Blood pressure monitoring should be proactive — particularly in dietary contexts of higher sodium intake — and home monitoring allows GG individuals to observe their own salt sensitivity in real time.

Interactions

rs8094327 is in strong LD with rs4149601 (r² ≈ 0.95), the primary functional variant at this locus, and the two should be interpreted together. The combination of rs4149601 GG with rs2288774 CC at NEDD4L represents the salt-sensitivity compound haplotype with the strongest documented effects on plasma renin, Nt-proANP, and cardiovascular outcomes.

The NEDD4L pathway interacts with the renin-angiotensin-aldosterone system (RAAS): when ENaC is active and sodium is retained, plasma renin is appropriately suppressed. Individuals with the GG-associated high-ENaC phenotype already have low renin activity, which means ACE inhibitors and ARBs — drugs that work by interrupting RAAS — are mechanistically less well-matched than diuretics that directly reduce tubular sodium reabsorption. This gene-drug interaction has direct clinical relevance if hypertension develops.

NEDD4L is also involved in regulating the thiazide-sensitive cotransporter NCC in the distal tubule, and in broader ubiquitin-mediated regulation of TGF-β signaling. Variants affecting RAAS tone (e.g. ACE rs4646994, AGT rs699, AGTR1 rs5186) may compound with NEDD4L haplotype to set the overall blood pressure trajectory.

Every day your airways face pollutants, allergens, and viruses. When epithelial cells lining the lung are damaged, they release an alarmin called IL-33 (interleukin-33)¹¹ IL-33 (interleukin-33)
An alarmin cytokine stored in the nuclei of epithelial cells and released upon tissue damage; it activates the immune system via the ST2 receptor on mast cells, ILC2s (group 2 innate lymphoid cells), eosinophils, and Th2 cells, driving the type 2 inflammatory response responsible for allergic asthma. IL-33 is a key initiator of the cascade that culminates in airway narrowing, mucus hypersecretion, and the eosinophilic inflammation that defines most asthma. A small fraction of people in European populations carry a rare variant in the IL33 gene — rs146597587-C — that essentially disables this alarmin and dramatically reduces their susceptibility to asthma and allergic airway disease.

The Mechanism

The rs146597587 variant disrupts a canonical splice acceptor site²² splice acceptor site
A splice acceptor is the AG dinucleotide at the 3' end of an intron; the spliceosome recognises this signal to cut the intron out and join the flanking exons together into mature mRNA. Disrupting it prevents normal splicing at the boundary of the last intron and the final coding exon (exon 7) of the IL33 transcript. When the C allele is present, the spliceosome fails to recognise the splice site, and approximately half of IL33 transcripts in a heterozygous carrier retain the last intron. That intron contains a premature stop codon, so the retained-intron mRNA is translated into a truncated protein — IL-33(1–204) — that is 66 amino acids shorter than the full-length IL-33(1–270).

The truncated protein is not simply a weak version of IL-33: it has entirely normal intracellular localisation but cannot bind the IL-33 receptor ST2³³ cannot bind the IL-33 receptor ST2
ST2 (also called IL-1RL1) is the cell-surface receptor for IL-33; binding triggers the MyD88 signalling cascade and NF-κB activation that drives inflammatory gene expression in mast cells, ILC2s, and eosinophils and fails to activate ST2-expressing cells. The C allele therefore functions as a true loss-of-function allele, and heterozygous carriers show approximately 40% lower total IL33 mRNA⁴⁴ 40% lower total IL33 mRNA
The retained-intron transcripts are subject to nonsense-mediated mRNA decay, reducing the pool of functional message compared to non-carriers — a direct readout of the haploinsufficiency effect.

The Evidence

The foundational study was conducted by Smith et al. 2017⁵⁵ Smith et al. 2017
A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genetics, March 2017. Primary analysis in the Icelandic whole-genome-sequenced cohort; replication across European populations. The team identified rs146597587-C at a frequency of 0.65% in the Icelandic population and replicated it across European cohorts. The protective effect on asthma was striking: OR = 0.47 (95% CI 0.32–0.70, P = 1.8×10⁻⁴) in 6,465 cases and 302,977 controls. Heterozygous carriers of the C allele had more than half the asthma risk of non-carriers. On eosinophils — a key effector cell in allergic inflammation — the effect was even more statistically dramatic: β = −0.21 SD (P = 2.5×10⁻¹⁶) in 103,104 individuals, confirming that reducing IL-33 output directly dampens eosinophilic inflammation.

Independent replication came from the Blood-Cell Consortium (Mousas et al. 2017)⁶⁶ Blood-Cell Consortium (Mousas et al. 2017)
Rare coding variants pinpoint genes that control human hematological traits. PLoS Genetics, August 2017. Analysed 137,086 rare variants across 308,572 participants and 15 haematological traits, which found rs146597587 associated with reduced eosinophil count at P = 2.4×10⁻²³ — ten orders of magnitude beyond genome-wide significance. That study also independently confirmed the asthma protection (OR 0.56, P = 2.6×10⁻⁷) and extended the finding to allergic rhinitis (OR 0.55, P = 4.2×10⁻⁴), demonstrating that the protective effect spans the full spectrum of type-2 allergic disease.

At a population level, the variant's rarity (C allele frequency ~0.4% in Europeans, effectively absent in African and South Asian populations) means it contributes minimally to population-level asthma variance — but for the individual carrier, the protection is large and mechanistically certain. The UK Biobank pLOF analysis (Emdin et al. 2018)⁷⁷ UK Biobank pLOF analysis (Emdin et al. 2018)
Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nature Communications 2018; >400,000 UK Biobank participants confirmed IL33 pLOF variants among a select group of genetic variants that protect against asthma and allergic disease across the largest biobank dataset available at the time.

The mechanism is directly therapeutically validated: the anti-IL-33 monoclonal antibody itepekimab (which pharmacologically mimics what this variant does genetically) demonstrated in a Phase 3 trial (Wechsler et al. 2021)⁸⁸ (Wechsler et al. 2021)
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. NEJM 2021 a 53% reduction in asthma-control-loss events (OR 0.42) and significant eosinophil reduction. This drug-genetics convergence is among the clearest validations in respiratory immunology: the same pathway disrupted by this natural variant is the target of a clinically approved treatment.

Practical Implications

For C allele carriers, the primary implication is genuine biological protection against type-2 driven asthma and allergic airway disease. This is not a statistical approximation — the mechanism is completely characterised and directly validated by therapeutic evidence. The protection is most clinically meaningful in the context of other asthma risk factors: individuals who are C allele carriers but have significant allergen exposure, smoking history, or other genetic susceptibility factors may still develop asthma, though at meaningfully reduced rates.

Because eosinophil counts are reliably lower in C allele carriers (not merely during attacks but as a baseline haematological trait), clinicians interpreting blood counts in heterozygous individuals should be aware that a "low-normal" eosinophil count may reflect this variant rather than an underlying deficiency.

Interactions

The IL-33/ST2 signalling axis interacts with several other innate immune pathways. The TSLP (thymic stromal lymphopoietin) alarmin, encoded by TSLP and regulated by variants including rs1837253, amplifies ILC2 activation in parallel with IL-33. Individuals with high-TSLP variants may have attenuated benefit from the IL33 protective allele, since TSLP can activate ILC2s even without IL-33. Similarly, IL-1RL1 (ST2) variants including rs992969 affect receptor expression levels and may modify the downstream consequences of reduced IL-33 output. The GWAS Catalog records strong associations at the IL33 locus (rs1420101 as the common sentinel GWAS SNP for asthma risk) that are independent of rs146597587 and reflect different regulatory variants in the same gene.

The speed at which you process information — swapping symbols for digits, following sequences, reacting to stimuli — has a measurable heritable component. One of the most robust genetic contributors identified through GWAS is a variant in CADM2¹¹ CADM2
Cell Adhesion Molecule 2, also called SynCAM2 — a synaptic adhesion protein that bridges pre- and post-synaptic membranes and is essential for forming and stabilising glutamatergic synapses. The rs17518584 C/T variant sits within an intron of CADM2 and reached genome-wide significance (P=3.28×10⁻⁹) for information processing speed in one of the largest cognitive GWAS conducted in non-demented older adults.

The Mechanism

CADM2 encodes a member of the SynCAM (synaptic cell adhesion molecule) immunoglobulin superfamily. Its protein product spans the synaptic cleft, mediating homophilic and heterophilic adhesion between axonal terminals and dendritic spines. This structural role directly supports glutamate synapse density and stability²² glutamate synapse density and stability
Glutamate is the principal excitatory neurotransmitter; synapse density and maintenance are prerequisites for fast, efficient neural signal propagation. Gene set enrichment in the CADM2 processing speed GWAS identified glutamate signaling (P=7.2×10⁻¹⁵) and GABA transport (P=1.4×10⁻¹¹) as the most significantly enriched pathways, placing CADM2 squarely within the excitatory/inhibitory balance machinery that governs neural throughput.

The rs17518584 variant lies approximately 170 kb upstream of the major CADM2 transcript start site but resides within an alternative transcript's intron. Its functional effect is presumed regulatory — influencing CADM2 expression in the cingulate cortex³³ CADM2 expression in the cingulate cortex
The anterior cingulate cortex is a key hub for cognitive control, attention allocation, and processing speed, a region where CADM2 is highly expressed. Carriers of the T allele show higher processing speed scores, consistent with a variant-driven increase in synaptic adhesion molecule expression or stability.

The Evidence

Ibrahim-Verbaas et al. 2016⁴⁴ Ibrahim-Verbaas et al. 2016
GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Mol Psychiatry 21(2):189–197 conducted a two-stage meta-analysis in 20 discovery cohorts (up to 32,070 participants) and 20 replication cohorts. The primary measure was the Letter Digit Substitution Test (LDST) and Digit Symbol Substitution Task (DSST) — validated tools for processing speed and executive function. The T allele at rs17518584 reached P=3.28×10⁻⁹ in joint analysis after adjustment for age, sex, and education. The beta was +5.92 LDST units per T allele, a meaningful effect in a polygenic trait.

The association was independently confirmed in the larger Davies et al. 2018⁵⁵ Davies et al. 2018
Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat Commun 9:2098, which identified 148 loci for general cognitive function including the CADM2 region, demonstrating that the processing speed signal extends to broader cognitive performance.

CADM2 shows notable genetic pleiotropy: separate variants in the same gene are associated with BMI (rs13068138, P=10⁻¹⁶), cannabis use disorder (rs2875907, P=10⁻¹⁷), and alcohol consumption. Yan et al. 2018⁶⁶ Yan et al. 2018
Cadm2 regulates body weight and energy homeostasis in mice. Mol Metab 8:196–210 showed that Cadm2 deletion in obese mice reduced adiposity, improved insulin sensitivity, and increased energy expenditure — suggesting CADM2 exerts hypothalamic control over metabolic homeostasis alongside its synaptic adhesion role.

Practical Actions

The processing speed deficit associated with CC genotype reflects impaired synaptic adhesion molecule function in glutamatergic circuits. The most evidence-supported intervention is targeted cognitive training — specifically, processing speed training tasks (not general brain training games) that are shown to produce transferable gains in untrained speed tasks. This works through synaptic plasticity mechanisms that partially compensate for lower baseline synaptic adhesion scaffolding.

Magnesium is the most biologically proximate nutritional lever: magnesium gates NMDA receptor channels (the key glutamate receptors at CADM2-stabilised synapses) and sufficient brain magnesium levels support both presynaptic release site formation and long-term potentiation⁷⁷ long-term potentiation
LTP is the synaptic strengthening mechanism underlying learning and memory; it requires coordinated glutamate release, AMPA receptor insertion, and NMDA receptor co-activation. The L-threonate form penetrates the blood-brain barrier more effectively than other magnesium salts, making it the preferred form for targeting synaptic magnesium.

Phosphatidylserine supports synaptic membrane fluidity and integrity — the lipid bilayer that CADM2 protein is anchored to — and has independent evidence for modestly improving processing speed in adults.

Interactions

CADM2 is pleiotropic: the cognitive effect at rs17518584 occurs through a different mechanism from the metabolic and addiction effects at other CADM2 variants (rs13068138, rs2875907). These are independent GWAS loci and are not in strong LD with rs17518584. Within cognitive genetics, CADM2 processing speed effects may compound with variants in glutamate receptor genes (GRIN2A, GRIN2B) and dopamine signaling genes (COMT, DRD2) that also influence cognitive throughput. No formal compound action studies on rs17518584 in combination with other variants have been published.

The rs17696736 variant sits inside an intron of NAA25 (N-alpha-acetyltransferase 25) on chromosome 12q24, but its disease associations are better understood through the wider 12q24 locus¹¹ 12q24 locus
A cluster of genes on chromosome arm 12q, including SH2B3/LNK and ATXN2, that shows unusually broad association with autoimmune, metabolic, and cardiovascular conditions. rs17696736 acts as a tag SNP for this region, meaning it travels in linkage disequilibrium²² linkage disequilibrium
Physical co-inheritance of nearby variants; when one is measured the other can be inferred without direct genotyping with functional variants in neighboring genes. In genome-wide association studies, carrying the G allele has been consistently associated with elevated risk for type 1 diabetes and juvenile idiopathic arthritis, and minor associations with serum lipids and urate have also been reported.

The Mechanism

The principal causal gene at this locus is thought to be SH2B3 (also called LNK), which encodes an adaptor protein that suppresses cytokine receptor signaling downstream of JAK2³³ suppresses cytokine receptor signaling downstream of JAK2
LNK physically binds JAK2 and thrombopoietin receptor, acting as a brake on white blood cell proliferation and cytokine amplification loops. When SH2B3 function is reduced through regulatory variants tagged by rs17696736-G, the brake on immune cell proliferation weakens, predisposing toward excessive lymphocyte and myeloid cell activation. A second gene, ATXN2 (ataxin-2), lies immediately adjacent to SH2B3 and regulates RNA processing; variants in this gene are hypothesized to contribute to the metabolic arm of the 12q24 phenotype — insulin resistance and lipid dysregulation — while SH2B3 variants primarily explain the autoimmune arm.

NAA25 itself is the auxiliary (scaffolding) subunit of the NatB N-terminal acetyltransferase complex, which co-translationally acetylates the N-terminus of roughly 20% of all human proteins⁴⁴ acetylates the N-terminus of roughly 20% of all human proteins
N-terminal acetylation modulates protein stability, localization, and protein-protein interactions; substrates include Bax, actin, and multiple metabolic enzymes. Whether the intronic variant directly alters NAA25 expression or is purely a surrogate for nearby functional variation remains unresolved. The available evidence points to SH2B3 as the primary driver of autoimmune association at this locus.

The Evidence

The 12q24 locus was first confirmed as a T1D susceptibility region by Todd et al. in a 2007 Nature Genetics GWAS⁵⁵ Todd et al. in a 2007 Nature Genetics GWAS
Four new chromosome regions confirmed: 12q24, 12q13, 16p13, 18p11; P_overall ≤ 1.15×10⁻¹⁴ for 12q24 spanning >4,000 T1D cases. The rs17696736 SNP specifically was tested in an Estonian case-control study by Douroudis et al.⁶⁶ Douroudis et al.
154 T1D patients vs. 230 controls; rs17696736 G allele: OR=1.53, 95% CI 1.14–2.04, p=0.0046, which confirmed that G allele carriers had a 53% higher T1D risk compared to AA homozygotes. A follow-up Estonian study by Kisand and Uibo⁷⁷ Kisand and Uibo
65 LADA, 154 T1D, 260 T2D patients and 229 controls found rs17696736 remained part of an optimized T1D prediction model alongside HLA-DQB1, insulin gene, PTPN22, CTLA4, and CD226 variants, but notably did NOT contribute to LADA prediction — underscoring that this locus tags classic type 1 diabetes autoimmunity rather than the more slowly progressive autoimmune diabetes spectrum.

In juvenile idiopathic arthritis, rs17696736 was independently replicated across two studies: Prahalad et al. 2009⁸⁸ Prahalad et al. 2009
445 JIA cases, 643 controls; OR=1.20, p=0.041 and Thompson et al. 2010⁹⁹ Thompson et al. 2010
>6,000 participants; OR=1.19, p=2.59×10⁻⁵. This supports the concept that the 12q24 locus confers shared autoimmune susceptibility across multiple conditions — a pattern now recognized for several immune regulatory loci. A 2010 childhood stroke study found no association between rs17696736 and ischemic stroke in children, placing this variant squarely in the autoimmune rather than vascular domain.

Secondary GWAS associations include modest effects on HDL, LDL, and total cholesterol (beta ~0.02 standard deviations per allele), and an inverse association with serum urate levels — G carriers have marginally lower urate, potentially reflecting SH2B3/ATXN2 effects on purine metabolism. Effect sizes are small and clinical relevance is modest compared to the autoimmune associations.

Practical Implications

For G allele carriers, the primary actionable implication is awareness of autoimmune disease susceptibility — specifically type 1 diabetes and inflammatory arthritis. The G allele frequency in European populations (~40–43%) means heterozygosity (AG) is actually the most common genotype in Europeans, whereas GG homozygosity (~13–18%) carries the largest additive risk increment. East Asian populations are almost entirely AA at this locus, consistent with lower T1D rates in East Asian populations.

Unlike strongly autoimmune-specific HLA variants, the 12q24 signal has a modest per-allele OR (~1.2–1.5 per study), meaning it contributes as one piece of a polygenic T1D risk picture rather than dominating risk individually. It is most useful in the context of a multi-locus T1D genetic risk score.

Interactions

rs17696736 operates in the same 12q24 locus as rs653178 (ATXN2/SH2B3), which is the lead GWAS SNP for multiple autoimmune conditions including T1D, celiac disease, hypertension, and asthma. These two SNPs are in strong linkage disequilibrium in European populations. The combined effect of SH2B3 dysregulation (autoimmune predisposition) and ATXN2 variation (metabolic predisposition) is hypothesized to jointly explain why T1D patients commonly show features of both autoimmunity and metabolic dysfunction.

Epistatic interactions have been noted with PTPN22 (rs2476601) — the tyrosine phosphatase that acts in the same T-cell signaling pathway. rs2476601 is one of the strongest non-HLA T1D risk variants (OR ~1.7–2.0 for heterozygotes); when combined with 12q24 risk variants, the cumulative probability of T1D rises meaningfully above either variant alone, though the specific compound genotype data for rs17696736 + rs2476601 is not available in the literature.

The R197Q variant (rs1799930) is another common slow acetylator allele in the NAT2 gene. It changes arginine to glutamine at position 197 of the enzyme, affecting protein stability and catalytic activity. This variant characterizes the NAT2*6A haplotype.

The Mechanism

Arginine at position 197 forms important salt bridges ¹¹ Salt bridges are electrostatic bonds between oppositely charged amino acids that help hold a protein's 3D shape together that stabilize the NAT2 protein structure. Replacing it with glutamine (A allele) disrupts these interactions, making the enzyme less stable and more prone to degradation. The result is lower steady-state enzyme levels and slower acetylation capacity.

Determining Your Acetylator Status

Your overall NAT2 acetylator phenotype ²² Your acetylator phenotype is how fast you actually metabolize NAT2 substrates, determined by which combination of alleles you inherited depends on the combination of all three major variants: rs1801280 (I114T), rs1799930 (R197Q), and rs1208 (R268K). Having two slow alleles at any combination of these positions makes you a slow acetylator. Having one slow and one rapid allele makes you intermediate, and having no slow alleles makes you a rapid acetylator.

Population Genetics

The frequency of slow acetylator alleles varies dramatically across populations. About 50-60% of Europeans and Africans are slow acetylators, while only about 10-20% of East Asians are. This variation likely reflects different dietary and environmental selective pressures throughout human history. Unlike I114T (rs1801280) which is very rare in East Asians, R197Q has a more uniform global distribution (~23-36% across populations).

Drug Implications

NAT2 status affects the metabolism of several medications beyond isoniazid. Sulfasalazine (for inflammatory bowel disease), hydralazine (for hypertension), and procainamide (for arrhythmias) are all NAT2 substrates. ³³ These drugs are rarely used today in general practice, but isoniazid remains a frontline tuberculosis treatment worldwide Slow acetylators may experience more side effects from these drugs at standard doses.

Metabolic Associations

Recent research has also identified NAT2 as an insulin sensitivity gene⁴⁴ insulin sensitivity gene
Knowles JW et al. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J Clin Invest, 2015, with slow acetylator status associated with decreased insulin sensitivity independent of BMI. This adds a metabolic dimension to NAT2 pharmacogenomics.

Resistin is an adipokine — a signaling molecule secreted primarily by macrophages in human adipose tissue — that acts as a brake on insulin action and an accelerator of inflammation. Unlike in rodents where it comes from fat cells directly, human resistin is mainly produced by macrophages infiltrating adipose tissue¹¹ macrophages infiltrating adipose tissue
This macrophage origin makes human resistin more of an inflammatory signal than a pure metabolic hormone, linking metabolic dysfunction to chronic low-grade inflammation. The rs1862513 -420C>G polymorphism sits in the RETN gene's promoter region and acts as a molecular volume knob: the G allele turns the gene up, increasing resistin production and widening its downstream consequences for insulin sensitivity, liver fat, and cardiovascular risk.

The Mechanism

The -420 position in the RETN promoter is a binding site for two transcription factors, Sp1 and Sp3²² Sp1 and Sp3
Specificity protein 1 and 3 — zinc-finger transcription factors that activate many housekeeping and metabolic genes by binding GC-rich promoter elements. The C allele at this position does not permit this binding. The G allele creates the binding motif that allows Sp1 and Sp3 to dock and drive RETN transcription. Laboratory experiments confirmed that overexpression of Sp1 or Sp3 enhanced RETN promoter activity specifically with the -420G allele³³ overexpression of Sp1 or Sp3 enhanced RETN promoter activity specifically with the -420G allele
Not the -420C allele, demonstrating allele- specific promoter activation. The result is measurably higher fasting serum resistin in G allele carriers, with the GG genotype showing the highest levels. Higher resistin impairs insulin signaling in muscle and liver, promotes hepatic fat deposition, and stimulates inflammatory cytokines including TNF-alpha and IL-6.

The Evidence

The functional discovery by Osawa et al. 2004⁴⁴ Osawa et al. 2004
Osawa H et al. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Diabetologia, 2004 in a Japanese cohort identified the GG genotype as associated with T2DM (adjusted OR 1.97) and found it could accelerate disease onset by 4.9 years. The association with resistin levels was independently confirmed in the Framingham Offspring Study⁵⁵ Framingham Offspring Study
Hivert MF et al. 2009 — 2,531 participants followed for 28 years, where the -420C/G association with plasma resistin remained significant (P = 0.0009) in combined meta-analysis, though with high heterogeneity across studies.

A 2022 meta-analysis⁶⁶ 2022 meta-analysis
Zhao X et al. Frontiers in Endocrinology, 2022 — 23 case-control studies, 10,651 T2DM cases and 14,366 controls found no overall T2DM association, but detected a strong age-modifying effect: in patients under 50, the GG genotype carried substantially elevated diabetes risk (OR 3.14-4.76), while in those over 50 it appeared neutral or slightly protective — a striking finding that may reflect survivor bias, population heterogeneity, or differential expression at different life stages. This age interaction warrants further study.

Beyond diabetes, the GG genotype is associated with non-alcoholic fatty liver disease⁷⁷ non-alcoholic fatty liver disease
NAFLD case-control study: GG vs CC OR 2.3, 95% CI 1.1-4.8 and with colorectal and breast cancer risk in Caucasians⁸⁸ colorectal and breast cancer risk in Caucasians
Meta-analysis of 9 studies (1,951 cases): dominant model OR 1.19, 95% CI 1.05-1.35, consistent with resistin's pro-inflammatory and pro-proliferative signaling properties.

Practical Actions

The most actionable finding is that GG carriers respond more strongly to dietary and pharmacological interventions that lower resistin. Two hypocaloric diet trials in obese Caucasians found that GG carriers showed significantly greater reductions⁹⁹ GG carriers showed significantly greater reductions
Insulin decreased -5.6 vs -2.9 mUI/L, HOMA-IR decreased -2.5 vs -0.6, glucose decreased -7.2 vs -0.8 mg/dL; all p<0.05 in insulin, HOMA-IR, fasting glucose, and LDL-cholesterol on calorie-restricted diets compared to C allele carriers. This means that despite higher baseline insulin resistance, GG individuals gain more from dietary intervention — a clinically useful reversal of expectations.

The Toon Genome Study¹⁰¹⁰ Toon Genome Study
Tanaka S et al. 2017 — 1,981 Japanese community-dwellers demonstrated that n-3 polyunsaturated fatty acid (PUFA) intake was inversely associated with serum resistin across all genotypes, but the inverse association was strongest in GG carriers¹¹¹¹ strongest in GG carriers
Resistin ranged from 18.9 ng/mL in the lowest n-3 PUFA quartile to 14.5 ng/mL in the highest, p=0.001; genotype-intake interaction p=0.004, with minimal effect in CC carriers. This genotype-specific response to omega-3 intake is directly actionable.

A small pilot study also found that the GG genotype predicted greater response to pioglitazone¹²¹² predicted greater response to pioglitazone
G/G genotype was independent predictor of FPG reduction, P=0.020, and HOMA-IR reduction, P=0.012 — a thiazolidinedione insulin sensitizer — in T2DM patients, suggesting pharmacogenomic relevance worth discussing with a prescribing physician if diabetes medications are being considered.

Monitoring serum resistin, fasting insulin, and HOMA-IR provides direct feedback on how well diet and lifestyle changes are working for GG carriers.

Interactions

The rs3219175 variant (c.-358G>A, also written as SNP-358) in the RETN promoter interacts with rs1862513. Japanese studies show that the G-A haplotype (combining -420G and -358A) produces the highest plasma resistin levels¹³¹³ highest plasma resistin levels
SNP-358 A allele is required for -420G to confer maximum resistin elevation in the Japanese population, greater than either variant alone. For those carrying GG at rs1862513, knowing the rs3219175 genotype provides additional resolution on resistin expression.

The PPARG rs1801282 Pro12Ala variant also interacts with rs1862513: in Japanese populations, PPARgamma Pro/Pro combined with -420 G/G genotype was synergistically associated with higher plasma resistin¹⁴¹⁴ PPARgamma Pro/Pro combined with -420 G/G genotype was synergistically associated with higher plasma resistin
Synergistic interaction detected in a general Japanese community study. Since PPARgamma is the primary transcription factor through which thiazolidinediones work, this interaction may partly explain the genotype-specific pioglitazone response.

CYP2C8¹¹ CYP2C8
Cytochrome P450 family 2, subfamily C, member 8 — a liver enzyme responsible for metabolizing roughly 5% of marketed drugs is a workhorse of hepatic drug clearance. Unlike its close relative CYP2C9, CYP2C8 handles a distinct substrate portfolio: the cancer drug paclitaxel, the diabetes drugs rosiglitazone and repaglinide, the antimalarial amodiaquine, and the NSAIDs ibuprofen and diclofenac. Beyond drug metabolism, CYP2C8 converts arachidonic acid into epoxyeicosatrienoic acids (EETs)²² epoxyeicosatrienoic acids (EETs)
signaling lipids with anti-inflammatory and vasodilatory properties, making it relevant to cardiovascular homeostasis. The intronic variant rs1934980 (G allele, ~19% globally) appears to influence CYP2C8 activity — not by changing the enzyme's amino acid sequence, but likely by altering how much protein the gene produces.

The Mechanism

rs1934980 sits within an intron of CYP2C8 on chromosome 10 (GRCh38 position 95,049,216). Intronic variants can affect mRNA splicing efficiency, transcription factor binding sites, or enhancer activity, all of which alter enzyme expression levels without changing the protein's structure. The G allele falls within a haplotype cluster — rs1934951, rs1934980, rs1341162, and rs17110453 — that segregates together across the CYP2C8 gene due to linkage disequilibrium³³ linkage disequilibrium
tendency for nearby variants to be inherited as a unit rather than independently. Saito et al. (2007)⁴⁴ Saito et al. (2007)
CYP2C8 haplotype structures and paclitaxel pharmacokinetics, Pharmacogenetics and Genomics identified intronic CYP2C8 haplotype groups in 437 Japanese individuals where strong linkage disequilibrium throughout the gene meant that intronic tag SNPs could capture expression differences associated with the broader haplotype — including elevated paclitaxel metabolite levels, suggesting altered enzyme turnover.

The Evidence

The most compelling clinical signal comes from a 2008 genome-wide SNP study by Sarasquete et al.⁵⁵ Sarasquete et al.
Blood, 2008 that examined 22 multiple myeloma patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ) against 65 matched controls. Among four significant CYP2C8 variants, rs1934980 showed p = 4.2×10⁻⁶ between cases and controls. The biological plausibility rests on CYP2C8's role in metabolizing the bisphosphonate zoledronic acid and its production of EETs that protect bone vasculature. Follow-up evidence is mixed: Such et al. (2011)⁶⁶ Such et al. (2011)
Haematologica, n=79 could not replicate the association for rs1934951, though a meta-analysis (2013)⁷⁷ meta-analysis (2013)
Zhong et al., Acta Haematol recovered a significant signal for rs1934951 in multiple myeloma patients specifically (dominant model OR=5.77, p=0.028). Because rs1934980 is in strong LD with rs1934951, its effect likely tracks the same haplotype.

The clopidogrel connection emerged in a 2024 pharmacogenomic polygenic study of 935 Chinese CAD patients⁸⁸ 935 Chinese CAD patients
Zhang et al., Clinical Therapeutics where rs1934980 was nominally associated with recurrent ischemic events — consistent with CYP2C8 contributing to the metabolic conversion of clopidogrel's intermediate forms. The overall polygenic model (including rs1934980) predicted a hazard ratio of 1.87 for high risk-allele burden (p=0.04), though the individual variant contribution was not reported separately.

For the canonical CYP2C8 substrates, functional work on haplotype-defined alleles is clearest for CYP2C8*3 (which shares partial haplotype background with this variant cluster). Dawed et al. (2016)⁹⁹ Dawed et al. (2016)
Diabetes Care, n=833 demonstrated that CYP2C8*3 carriers had a reduced HbA1c response to rosiglitazone (p=0.01), and Marcath et al. (2019)¹⁰¹⁰ Marcath et al. (2019)
Pharmacogenomics, n=58 found CYP2C8*3 carriers had shorter paclitaxel exposure (p=0.006).

Practical Actions

Carriers of one or two G alleles at rs1934980 should be aware of this variant's relevance to their medication history — particularly for paclitaxel-based chemotherapy regimens, thiazolidinediones (rosiglitazone, pioglitazone), and repaglinide. If ever receiving intravenous bisphosphonates (zoledronic acid, pamidronate) for cancer-related bone disease or osteoporosis, the association with BRONJ risk warrants heightened dental surveillance. The cardiovascular relevance — through both clopidogrel response and EET production — makes this variant one to flag for cardiologists managing antiplatelet therapy in homozygous G carriers.

Interactions

rs1934980 is in strong linkage disequilibrium with rs1934951, rs1341162, and rs17110453 — all four variants were co-identified in the Sarasquete BRONJ GWAS and likely travel together as a CYP2C8 intronic haplotype. The combined effect of carrying this CYP2C8 haplotype alongside impaired CYP2C19 function (rs4244285, rs4986893) could compound altered clopidogrel activation, since both enzymes contribute to the drug's bioactivation pathway. An interaction with CYP2C9 variants (rs1799853, rs1057910) is also plausible for shared NSAID substrates.

AGER encodes RAGE (Receptor for Advanced Glycation End-Products), a pattern recognition receptor¹¹ pattern recognition receptor
A cell-surface protein that detects molecular signatures of tissue damage, pathogen invasion, or cellular stress — triggering immune responses in the immunoglobulin superfamily. RAGE is found on endothelial cells, neurons, immune cells, and lung epithelium. Its ligands include advanced glycation end-products²² advanced glycation end-products
Proteins and lipids that have been irreversibly modified by sugar molecules — they accumulate with diabetes, aging, and diets high in processed foods, HMGB1 (a nuclear protein released during cell injury), S100 proteins, and amyloid-beta. When ligands bind RAGE, the receptor activates NF-κB and MAPK cascades, driving sustained inflammatory gene expression.

The rs2070600 variant substitutes glycine for serine at position 82 in RAGE's ligand-binding V domain. This is one of the most functionally well-characterized common RAGE polymorphisms: the T (Ser82) allele has been consistently associated with substantially lower levels of soluble RAGE (sRAGE)³³ soluble RAGE (sRAGE)
A truncated, secreted form of RAGE that acts as a decoy receptor — it binds and sequesters AGEs and other RAGE ligands in circulation, preventing them from activating cell-surface RAGE and dampening inflammatory signaling. Because sRAGE decoys circulating AGEs away from membrane-bound RAGE, lower sRAGE means more inflammatory signal reaches cells — a "gain of inflammation" effect.

The Mechanism

RAGE Gly82Ser is a missense change in the V-domain immunoglobulin fold⁴⁴ immunoglobulin fold
The structural domain responsible for ligand binding in the RAGE extracellular region; substituting Ser for Gly at position 82 alters local conformation near the ligand-binding pocket that binds AGEs and HMGB1. The key functional consequence is impaired shedding of the soluble receptor form. When cells expressing the Ser82 variant are stimulated with HMGB1, they produce significantly less sRAGE than Gly82 cells (P=0.036), as demonstrated by Miller et al. (2016)⁵⁵ Miller et al. (2016)
Miller S et al. The Ser82 RAGE variant affects lung function and serum RAGE in smokers and sRAGE production in vitro. Biochim Biophys Acta, 2016.

In a large community-based population study, Maruthur et al. (2015)⁶⁶ Maruthur et al. (2015)
Maruthur NM et al. Genetics of plasma soluble receptor for advanced glycation end-products and cardiovascular outcomes. PLoS One, 2015 showed that the T allele was associated with approximately 50% lower sRAGE levels in 1,737 white participants (P=7.26×10⁻¹⁶) and similarly in 581 Black participants, with AGER variants explaining 21–26% of the entire variance in circulating sRAGE. The net effect: T allele carriers have less circulating decoy receptor and thus more unopposed membrane-bound RAGE activation when ligands are present.

AGE accumulation in tissues — driven by hyperglycemia, aging, and dietary AGE intake — is the primary driver of RAGE activation. RAGE in turn activates NF-κB, JAK/STAT, and MAPK signaling cascades, generating a self-amplifying inflammatory loop. In the brain, this AGE-RAGE-NF-κB axis disrupts the blood-brain barrier, activates microglia, and contributes to the neuroinflammatory milieu implicated in cognitive decline and neurodegeneration.

The Evidence

Lung disease. The most extensively studied phenotype is pulmonary, where RAGE plays a central role in alveolar homeostasis. In idiopathic pulmonary fibrosis (IPF), Yamaguchi et al. (2017)⁷⁷ Yamaguchi et al. (2017)
Yamaguchi K et al. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. Respirology, 2017 found that the rs2070600 minor allele was significantly more common in 87 IPF patients than in 303 controls (OR=1.84, 95% CI 1.08–3.10). Reduced sRAGE also predicted acute exacerbation and was an independent predictor of 5-year survival (HR=7.96). In combined pulmonary fibrosis and emphysema (CPFE), Kinjo et al. (2020)⁸⁸ Kinjo et al. (2020)
Kinjo T et al. The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in CPFE in Japanese patients. Scientific Reports, 2020 found OR=1.93 (Pc=0.018) for CPFE vs. COPD in a dominant model (n=448 Japanese patients). Sin et al. (2022)⁹⁹ Sin et al. (2022)
Sin S et al. Association between plasma sRAGE and emphysema according to the genotypes of AGER gene. BMC Pulmonary Medicine, 2022 demonstrated that in CC-genotype COPD patients (n=436), high sRAGE independently protected against emphysema (OR=0.24, 95% CI 0.11–0.51) — but this protective association was entirely absent in TC/TT carriers, whose RAGE shedding is blunted.

Diabetes and metabolic disease. A meta-analysis by Cheng et al. (2021)¹⁰¹⁰ Cheng et al. (2021)
Cheng Z et al. Ethnicity-dependent contribution of AGER gene in the pathogenesis of type 2 diabetes. Endocrine Journal, 2021 analyzed 29 studies (8,318 T2D cases, 5,589 controls) and found that in Caucasian populations rs2070600 conferred a 2.13-fold increased risk of type 2 diabetes (95% CI 1.28–3.55, I²=42.5%). In type 1 diabetes, Salonen et al. (2014)¹¹¹¹ Salonen et al. (2014)
Salonen KM et al. Associations of sRAGE concentrations with AGER gene polymorphisms in children with type 1 diabetes. Diabetes Care, 2014 found that the rs2070600 AA (CC in plus-strand) genotype associated with decreased sRAGE concentrations in 2,115 children, and lower sRAGE reflected more aggressive disease presentation.

Neuroinflammation and Alzheimer's risk. RAGE is the primary receptor for amyloid-beta aggregates, and its activation drives NF-κB-mediated neuroinflammation that accelerates Alzheimer's pathology. A study by Deo et al. (2020)¹²¹² Deo et al. (2020)
Deo P et al. APOE ε4 carriers have a greater propensity to glycation and sRAGE which is further influenced by RAGE G82S polymorphism. J Gerontol, 2020 in 172 cognitively normal individuals showed that APOE ε4 carriers with the Ser82 variant had the most pronounced glycation burden and altered sRAGE dynamics — a combination that may amplify neuroinflammatory risk compared to either variant alone.

AGEs and sleep. A 2024 cross-sectional study in 1,732 Chinese adults Li et al. (2024)¹³¹³ Li et al. (2024)
Li L et al. Associations of advanced glycation end products with sleep disorders in Chinese adults. Nutrients, 2024 found that higher plasma AGE levels (CML, CEL, MG-H1) were independently associated with poor sleep quality (OR 1.33–1.61 per interquartile range), insomnia, short sleep duration, and excessive daytime sleepiness. Because the Ser82 variant reduces the circulating decoy that scavenges AGEs, carriers operating under higher AGE loads — from diet, diabetes, or aging — may experience greater RAGE-mediated signaling that contributes to sleep-disrupting neuroinflammation. Direct genetic studies of rs2070600 and sleep are lacking; this connection is mechanistically inferred.

Practical Actions

The central intervention for T allele carriers is reducing the AGE load that activates RAGE. Dietary AGEs — formed when food is cooked at high heat (grilling, frying, broiling) — are absorbed and accumulate in tissues. Switching to moist heat cooking methods reduces dietary AGE intake by 50–70% without restricting food choices. Controlling blood glucose is doubly important: hyperglycemia both accelerates endogenous AGE formation and activates RAGE, compounding the reduced sRAGE buffering capacity in T allele carriers. Monitoring fasting glucose and HbA1c is especially relevant given the meta-analytic evidence of elevated T2D risk.

sRAGE levels are also modifiable: aerobic physical activity raises circulating sRAGE (a genotype-independent effect that partially compensates for the genetic deficit), and caloric restriction reduces the AGE load that drives RAGE signaling.

Interactions

The rs2070600 T allele interacts with APOE ε4 status to amplify glycation burden and neuroinflammatory risk. Deo et al. (2020) showed that APOE ε4 carriers already exhibit elevated AGE formation; when the Ser82 RAGE variant reduces sRAGE-mediated AGE clearance, the combination creates an environment of heightened RAGE activation that may compound amyloid-beta toxicity in Alzheimer's pathology. This T allele × APOE ε4 interaction warrants a compound action for users carrying both risk variants (see interaction_candidates below).

The Ser82 variant also interacts with other AGER promoter polymorphisms (rs1800624, rs1800625) in determining the overall RAGE expression level. Haplotype analyses suggest the combined promoter + coding variants may have stronger effects than any single SNP alone.

Most people know that omega-3 fatty acids protect the heart and brain, but far fewer know that the body's ability to make its own DHA from dietary precursors varies significantly by genetics. The ELOVL2 gene encodes elongase-2¹¹ elongase-2
An enzyme in the endoplasmic reticulum that extends the carbon chain of long-chain polyunsaturated fatty acids by two carbon units per catalytic cycle, the enzyme responsible for the final elongation steps in the omega-3 pathway: converting EPA (20:5) to DPA²² DPA
Docosapentaenoic acid (22:5 n-3) — an intermediate omega-3 that accumulates when the final step to DHA is impaired and DPA to DHA³³ DHA
Docosahexaenoic acid (22:6 n-3) — the dominant omega-3 in brain and retinal tissue, required for synaptic plasticity, visual function, and anti-inflammatory signaling. The rs2236212 variant, located in an intron of the ELOVL2 gene, is associated with reduced elongase activity and has measurable effects on circulating DHA levels, liver fat accumulation, and the magnitude of response to omega-3 supplementation.

The Mechanism

ELOVL2 is most highly expressed in the liver, where it catalyzes two sequential elongation reactions: EPA → DPA (24:5), then DPA → TPA (24:6), which is then desaturated and chain-shortened to DHA by the enzyme FADS2. The rs2236212 C allele is an intronic variant that does not alter the amino acid sequence of the protein, but appears to reduce the transcriptional output or splicing efficiency of the ELOVL2 gene, resulting in lower effective elongase activity. Maguolo and colleagues⁴⁴ Maguolo and colleagues
Maguolo A et al. Influence of genetic variants in FADS2 and ELOVL2 genes on BMI and PUFAs homeostasis in children and adolescents with obesity. Int J Obes, 2021 demonstrated this directly in a cohort of 1,649 obese Italian children: the rs2236212 C allele was significantly associated with reduced enzymatic elongation activity (p = 0.048), confirming that the genotype has a measurable functional consequence.

The downstream result is that C-allele carriers convert EPA to DHA less efficiently, causing EPA and DPA to accumulate at slightly higher levels while DHA production is blunted. This creates a scenario where baseline plasma DHA may be lower, but the precursor EPA is more readily available — which explains the paradox seen in supplementation studies.

The Evidence

The most directly informative study is by Alsaleh and colleagues⁵⁵ Alsaleh and colleagues
Alsaleh A et al. ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. Genes Nutr, 2014 who randomized 367 subjects to different fish oil doses. At the highest dose (1.8 g/day EPA+DHA), minor C-allele carriers showed approximately 30% higher plasma EPA and 9% higher DHA compared to GG homozygotes, with a highly significant genotype × treatment interaction (p < 0.0001 for EPA; p = 0.004 for DHA). At baseline, however, C-allele carriers had lower DHA proportions. This pattern — lower baseline DHA, larger supplementation response — is the hallmark of impaired endogenous elongation that can be partially rescued by exogenous DHA supply.

Large-scale population genetics supports this. The CHARGE Consortium meta-analysis⁶⁶ CHARGE Consortium meta-analysis
Lemaitre RN et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet, 2011 of 8,866 European adults found that ELOVL2 minor alleles were associated with higher EPA (p = 2×10⁻¹²) and DPA (p = 1×10⁻⁴³) but lower DHA (p = 1×10⁻¹⁵) in plasma phospholipids — exactly the pattern expected from a reduction in the EPA→DPA→DHA elongation cascade.

Beyond fatty acid composition, the rs2236212 C allele has also been linked to metabolic consequences of impaired DHA synthesis. In a cohort of 514 obese children, Zusi and colleagues⁷⁷ Zusi and colleagues
Zusi C et al. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Dig Liver Dis, 2019 found that rs2236212 was independently associated with a 34% higher odds of nonalcoholic fatty liver disease (NAFLD; OR = 1.34, p = 0.047). This is biologically plausible: DHA regulates hepatic lipid metabolism and reduces de novo lipogenesis; impaired DHA synthesis could contribute to hepatic fat accumulation.

Practical Implications

The key take-away for C-allele carriers — particularly CC homozygotes — is that the body's endogenous DHA production is constrained. This means dietary EPA (from flaxseed, chia seeds, walnuts) is a poor substitute for preformed DHA, because the elongation step that would convert EPA to DHA is exactly what is compromised. Preformed DHA from marine sources bypasses this bottleneck entirely.

The Alsaleh supplementation data also suggests that C-allele carriers are not unresponsive to omega-3s — quite the opposite. They appear to derive a larger relative increase in EPA and DHA from supplementation, meaning preformed DHA supplementation is both necessary and effective for this genotype.

Interactions

ELOVL2 functions downstream of the FADS desaturases in the omega-3 pathway. The FADS1 and FADS2 enzymes (encoded by variants including rs174547 and rs174537) perform the preceding desaturation steps, converting alpha-linolenic acid (ALA) to EPA. C-allele carriers at rs2236212 who also carry low-activity FADS variants face a compounded impairment across multiple steps of the omega-3 synthesis pathway. For these individuals, reliance on plant-based ALA is doubly ineffective — both the FADS desaturation step and the ELOVL2 elongation step are compromised. The ELOVL2 rs953413 variant is in linkage disequilibrium with rs2236212 in European populations and has been studied independently in relation to sex-specific differences in DHA response to EPA supplementation.

PPARδ¹¹ PPARδ
Peroxisome Proliferator-Activated Receptor delta — a nuclear receptor transcription factor that binds fatty acids and drives gene expression programs for fat oxidation, mitochondrial biogenesis, and muscle fiber remodeling sits at the intersection of genetics and exercise science: your genotype here doesn't change your resting fitness, but it does influence how strongly your aerobic capacity improves when you train. The rs2267668 SNP lies in an intronic region of PPARD (also annotated to the gene's 5' region in some transcript isoforms) and has been shown to influence skeletal muscle mitochondrial function and body composition responses to lifestyle intervention. This variant is the first of three tag SNPs in a PPARD haplotype block that has been linked to elite athlete status. rs2016520 (PPARD +294T>C, already profiled separately) is the primary functional PPARD variant affecting transcription; rs2267668 captures additional independent variance in training response that rs2016520 does not fully explain.

The Mechanism

Unlike the nearby rs2016520 variant — which alters an Sp-1 transcription factor binding site and directly modulates PPARD promoter activity — rs2267668 is an intronic variant without a confirmed direct regulatory mechanism. However, its functional fingerprint is real and measurable: laboratory analysis of skeletal muscle tissue from G-allele carriers shows reduced mitochondrial oxidative capacity in vitro²² reduced mitochondrial oxidative capacity in vitro
Measured by substrate oxidation assays in isolated skeletal muscle, which reflect the sum of mitochondrial density, respiratory chain enzyme activity, and beta-oxidation capacity compared to AA homozygotes. This suggests the G allele tags a local regulatory or splicing variation that subtly reduces PPARδ-driven mitochondrial biogenesis in muscle. The consequence is a blunted transcriptional response to exercise training — the adaptive machinery that normally expands mitochondrial density and fat-burning capacity in response to aerobic effort is less responsive in G-allele carriers.

The variant may also affect PPARD expression through chromatin-level mechanisms or by altering the ratio of transcript isoforms, effects that would not be captured by standard promoter reporter assays but would explain the in vitro mitochondrial phenotype. The exact molecular mechanism remains under investigation.

The Evidence

The key study establishing rs2267668 as a functional variant was a 9-month lifestyle intervention in individuals at increased risk for type 2 diabetes³³ 9-month lifestyle intervention in individuals at increased risk for type 2 diabetes
Stefan N et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab, 2007. After nine months of supervised diet and aerobic exercise, the G allele was independently associated with significantly blunted improvement in individual anaerobic threshold⁴⁴ individual anaerobic threshold
A precise physiological measure of aerobic fitness capacity — the exercise intensity at which lactate production exceeds clearance, marking the boundary between aerobic and anaerobic energy systems. Higher is better for endurance performance and metabolic health. (IAT). AA homozygotes showed +120% improvement in IAT and +40% improvement in insulin sensitivity; G-allele carriers showed only +11% and +4% respectively. The researchers simultaneously measured skeletal muscle mitochondrial function in vitro and confirmed lower oxidative capacity in G-allele carriers — establishing a mechanistic link between the genotype and the blunted training response.

A whole-body MRI study of 156 subjects at elevated type 2 diabetes risk⁵⁵ whole-body MRI study of 156 subjects at elevated type 2 diabetes risk
Thamer C et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab, 2008 found that G-allele carriers showed smaller reductions in total adipose tissue mass, smaller reductions in hepatic fat (liver fat), and smaller increases in relative leg muscle volume in response to lifestyle intervention, compared with AA homozygotes. The three PPARD variants studied (rs1053049, rs6902123, and rs2267668) each independently explained variation in body composition response, with their effects additive.

In the context of elite athletic performance, a haplotype analysis of 660 elite Polish athletes and 704 healthy controls⁶⁶ haplotype analysis of 660 elite Polish athletes and 704 healthy controls
Maciejewska-Karlowska A et al. Genomic haplotype within the Peroxisome Proliferator-Activated Receptor Delta (PPARD) gene is associated with elite athletic status. Scand J Med Sci Sports, 2014 examined the three-SNP PPARD haplotype (rs2267668 / rs2016520 / rs1053049). The A/C/C haplotype — carrying the rs2267668-A allele alongside the favorable rs2016520-C allele and rs1053049-C — was dramatically underrepresented in elite athletes across all sport categories (p < 0.000001). This finding reveals that the full haplotype context matters: even carrying the favorable rs2016520-C allele for transcription does not rescue elite performance potential when neighboring variants create an unfavorable haplotype configuration.

A 12-week training intervention in 168 Polish women⁷⁷ 12-week training intervention in 168 Polish women
Leońska-Duniec A et al. The polymorphisms of the PPARD gene modify post-training body mass and biochemical parameter changes in women. PLOS One, 2018 found a paradoxical lipid finding: G-allele carriers showed a 4.6% decrease in total cholesterol during training, while AA homozygotes showed significant increases in triglyceride levels — suggesting the G allele confers a modest lipid-handling difference during aerobic exercise, distinct from its effect on fitness capacity.

Practical Actions

If you carry the G allele (AG or GG), your aerobic fitness response to training is likely blunted compared to AA individuals. This does not mean exercise is less important — quite the opposite: because baseline mitochondrial function is lower, consistent aerobic training is more critical. The key adjustment is to allow a longer adaptation window (minimum 16–20 weeks rather than 8–12) and to prioritize training volume over intensity in initial phases to build the mitochondrial infrastructure your genotype builds more slowly.

If you are AA homozygous, you have the high-responder genotype for aerobic training adaptation. Your mitochondrial function responds strongly to exercise stimuli — structure training with progressive overload and adequate volume to exploit this aerobic trainability.

Regardless of genotype, omega-3 fatty acids (EPA and DHA) are natural PPARδ ligands and may support receptor activation in skeletal muscle. For G-allele carriers in particular, nutritional support for mitochondrial function — including omega-3s and ensuring adequate coenzyme Q10 and iron status — may partially offset the reduced genetic training response.

Interactions

The most important interaction documented for rs2267668 is with PPARGC1A rs8192678 (Gly482Ser)⁸⁸ PPARGC1A rs8192678 (Gly482Ser)
PGC-1alpha (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha) is the primary transcriptional coactivator that physically partners with PPARδ to drive mitochondrial biogenesis in response to exercise. The Gly482Ser substitution reduces this coactivation activity.: the Stefan et al. (2007) study found that carrying the minor alleles at BOTH rs2267668 (G) AND PPARGC1A rs8192678 (Ser) produced a compounded reduction in aerobic fitness response — IAT improved only +11% vs +120% in the double major-allele group, and insulin sensitivity improved only +4% vs +40%. This additive effect suggests these two variants impair the same receptor–coactivator partnership that links exercise stimuli to mitochondrial gene expression.

This variant is also one of three in the PPARD haplotype block (with rs2016520 and rs1053049). The haplotype interplay means individual SNP effects can be modulated by neighboring alleles — users who have been genotyped for all three variants can see their full PPARD haplotype in the compound analysis section.